# Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19

> **NCT04400799** · PHASE3 · TERMINATED · sponsor: **University of Zurich** · enrollment: 475 (actual)

## Conditions studied

- COVID-19
- Pulmonary Embolism, Deep Vein Thrombosis

## Interventions

- **DRUG:** Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml

## Key facts

- **NCT ID:** NCT04400799
- **Lead sponsor:** University of Zurich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-15
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-04-12
- **Target enrollment:** 475 (ACTUAL)
- **Why stopped:** due to results from interim analysis
- **Last updated:** 2022-05-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04400799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04400799, "Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04400799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*